GKIM
MRNA icon

GW&K Investment Management’s Moderna MRNA Stock Holding History

GW&K Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73K Buy
1,042
+683
+190% +$35.3K ﹤0.01% 525
2026
Q1 		$18K Buy
359
+22
+7% +$1.03K ﹤0.01% 795
2025
Q4 		$10K Sell
337
-45
-12% -$1.22K ﹤0.01% 864
2025
Q3 		$10K Buy
382
+20
+6% +$558 ﹤0.01% 860
2025
Q2 		$10K Buy
362
+168
+87% +$4.42K ﹤0.01% 853
2025
Q1 		$5K Buy
194
+34
+21% +$1.21K ﹤0.01% 912
2024
Q4 		$7K Buy
160
+10
+7% +$478 ﹤0.01% 846
2024
Q3 		$10K Sell
150
-14
-9% -$1.28K ﹤0.01% 784
2024
Q2 		$19K Buy
164
+39
+31% +$4.93K ﹤0.01% 580
2024
Q1 		$13K Buy
125
+9
+8% +$907 ﹤0.01% 634
2023
Q4 		$12K Sell
116
-1
-0.9% -$84 ﹤0.01% 629
2023
Q3 		$12K Buy
117
+5
+4% +$558 ﹤0.01% 576
2023
Q2 		$14K Buy
112
+110
+5,500% +$14.7K ﹤0.01% 526
2023
Q1 		$0 Buy
+2
New +$330 ﹤0.01% 556
2022
Q3 		– Sell
-42
Closed -$6K – 675
2022
Q2 		$6K Buy
42
+20
+91% +$2.86K ﹤0.01% 562
2022
Q1 		$4K Buy
+22
New +$3.7K ﹤0.01% 586

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

GW&K Investment Management's MRNA Position: Q2 2026 in Review

GW&K Investment Management increased its Moderna (MRNA) stake by 190% in Q2 2026, buying an estimated $35.3K and bringing the position to 1,042 shares worth $73K. The position accounts for ﹤0.01% of the portfolio, ranked #525.

GW&K Investment Management first reported a position in MRNA in Q1 2022 and has held it in 16 quarters since. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • GW&K Investment Management held 1,042 shares of Moderna worth $73K as of Q2 2026.
  • GW&K Investment Management bought 683 Moderna shares in Q2 2026, an estimated $35.3K.
  • Moderna made up ﹤0.01% of GW&K Investment Management's portfolio in Q2 2026, its #525 holding.
  • GW&K Investment Management first reported a position in Moderna in Q1 2022 and has held it in 16 quarters since.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.